The immunosuppressive and antiinflammatory cytokine interleukin (IL) 10 selectively upregulates the expression of the CC chemokine receptors CCR5, 2, and 1 in human monocytes by
prolonging their mRNA half-life. IL-10-stimulated monocytes display an increased number of
cell surface receptors for, and better chemotactic responsiveness to, relevant agonists than do
control cells. In addition, IL-10-stimulated monocytes are more efficiently infected by HIV
BaL. This effect was associated to the enhancement of viral entry through CCR5. These data
add support to an emerging paradigm in which pro- and antiinflammatory molecules exert reciprocal and opposing influence on chemokine agonist production and receptor expression.
 |
Introduction |
Chemokines are a superfamily of proteins that play a
crucial role in immune and inflammatory reactions
and in viral infections (1). Chemokines can be grouped
in two main subfamilies defined as CXC (or
) and CC (or
) according to the spacing of the first two cysteine residues (1, 3). Recently, the new chemokines lymphotactin
and fractalkine have been reported and define two additional classes of the chemokine superfamily (1, 3). Inflammatory cytokines (e.g., IL-1, TNF-
, and IL-6) and bacterial products are potent inducers of chemokine production
both in vitro and in vivo (1). Contrary to this, molecules
with immunosuppressive and antiinflammatory activity, such
as IL-10 and glucocorticoid hormones, inhibit chemokine
production (7, 8).
Chemokines bind to and activate seven-transmembrane
domain receptors (1, 9). Four receptors for the CXC
chemokines, named CXCR1-4, and eight for CC chemokines (CCR1-8) have been cloned and characterized in
leukocyte populations. With only a few exceptions, chemokine receptors bind multiple chemokines and recently it
was shown that some of them can function as entry/fusion cofactors for HIV-1 infection (4, 11).
The regulation of expression of chemokine receptors
may play a central role in the tuning of the chemokine action, but to date it has been the object of limited attention
(12). Here we report that the immunosuppressive and
antiinflammatory cytokine IL-10 (16) selectively upregulates the expression of CC chemokine receptors in human
mononuclear phagocytes by increasing the half-life of their
mRNA. This unexpected action is functionally relevant for
migration and HIV infection. These results are consistent with a novel paradigm of regulation of chemokines and
their receptors by pro- and antiinflammatory signals.
 |
Materials and Methods |
Monocytes.
PBMCs were obtained from buffy coats of healthy
blood donors. Monocytes were obtained by Ficoll (Biochrom,
Berlin, Germany) and Percoll (Pharmacia Biotech AB, Uppsala,
Sweden) gradients (19). Purity was >90% as assessed by immunofluorescence and FACS® analysis for cell suface expression of
CD14.
FACS® Analysis.
Cell staining was performed using monoclonal antibodies followed by FITC-conjugated affinity-purified,
isotype-specific goat anti-mouse antibody (Techno-Genetics Turin,
Italy). Anti-CD14 (IgG2a; gift of Dr. P. Beverly, Jemmer Institute, London, UK) and LS87 5C7 (anti-CCR5; IgG2a) (20) were
used. Mouse IgG2a, kappa (UPC10) (Sigma Chemical Co., St.
Louis, MO) was used as irrelevant control antibody. In some cases
results are expressed as relative fluorescence intensity (RFI), calculated according to the formula: RFI = mean fluorescence (sample)
mean fluorescence (control)/mean fluorescence (control).
Chemotaxis.
Monocyte migration was evaluated using a chemotaxis microchamber technique (NeuroProbe, Pleasanton, CA)
using polycarbonate filters (5 µm pore size; NeuroProbe), as previously described (19). Human recombinant monocyte chemotactic
protein (MCP)-1, macrophage inflammatory protein (MIP)-1
and
RANTES (regulated on activation, normal T cell expressed and
secreted) were from PeproTech Inc. (Rocky Hill, NJ). Human
rMIP-1
/LD78 was from Dr. L. Czaplewski (British Bio-technology Limited, Cowley, UK). Aminooxypentane (AOP)-RANTES
(gift of Dr. A.E.I. Proudfoot, Glaxo, Geneve, Switzerland) was prepared as previously described (21). The chamber was incubated at
37°C in air with 5% CO2 for 90 min. At the end of the incubation, filters were removed and stained with Diff-Quik (Baxter, Rome, Italy). Five high power oil-immersion fields were counted.
Northern Blot and Runoff Analysis.
RNA was extracted by the
guanidium thiocyanate method, and blotted and hybridized as
previously described (15). Probes were labeled by Megaprime
DNA labeling system (Amersham International, Buckinghamshire, UK) with
32P-dCTP (3000 Ci/mmol; Amersham). Membranes were prehybridized at 42°C in Hybrisol (Oncor, Inc.,
Gaithersburg, MD) and hybridized overnight with 106 cpm/ml of
32P-labeled probe. Membranes were then washed three times at
room temperature for 10 min in 0.2× SSC (1× SSC = 0.15 M
NaCl, 0.015 M sodium citrate, pH 7.0), 0.1% SDS, and then
washed twice at 60°C for 20 min in 0.2× SSC, 0.1% SDS before
being autoradiographed using Kodak XAR-5 films and intensifier
screens (Eastman Kodak Co., Rochester, NY) at
80°C. cDNA
probes were obtained as previously described (15). For CCR2
and CCR5, fragments of the open reading frame including a portion of the 3
-untranslated regions were generated by reverse transcriptase PCR from NK cell total RNA (14). The specificity of
the two probes was confirmed in Northern blot experiments using CCR2 and CCR5 single cell transfectants (data not shown).
HIV Assays.
Monocytes were plated in 24-well plates (Falcon, Becton-Dickinson Labware, Lincoln Park, NJ) at 0.5 × 106
cells/ml in RPMI 1640 (Bio Whittaker, Verviers, Belgium) supplemented of 10% FCS (Hyclone Europe, Oud-Beijerland, The
Netherlands). Monocytes were stimulated with IL-10 (0.1-10
ng/ml) for 6 h and then incubated in the presence and absence of
200 ng/ml of CC chemokines including RANTES, MIP-1
,
MIP-1
, and MCP-1, or of AOP-RANTES for 30 min before
HIV infection. The macrophage-tropic BaL strain of HIV-1, known
to infect CD4+ cells with the cooperation of CCR5 (22, 23), was
treated with 2 µg/ml of RQ1 RNase-free DNase (Promega,
Madison, WI) for 30 min at room temperature, and added to the
cultures at the multiplicity of infection of 0.1. Culture supernatants were collected at fixed intervals, stored at
80°C until
tested for a conventional analysis of their Mg2+-dependent reverse transcriptase activity (24). Aliquots (0.5 × 106 cells) of either untreated or IL-10-treated cells were harvested 1, 16, and 40 h
after infection, and were then centrifuged; cell pellets were stored
at
80°C until they were tested for proviral DNA synthesis. Cell
pellets were lysed by incubation at 56°C for 1 h with 250 µl of
a buffer of SDS-NaCl EDTA-Tris containing 1,200 µg/ml of proteinase K. PCR amplification of HIV-1 DNA was based on published methods (25, 26). In brief, 50 µl of lysed suspension were
diluted to 100 µl in a buffer containing 50 mM Tris (pH 8.5), 15 mM (NH4)SO4, 2.5 mM MgCl2, 10 µg BSA, 0.2 mM deoxynucleoside triphosphates, 0.5 µM of each oligonucleotide
primer, and Taq DNA polymerase (2 U; Perkin-Elmer Corp., Norwalk, CT). The region spanning U5 and leader sequence was
detected by using primers 5
-CTCTAGCAGTGGCGCCCG
AACA-3
and 5
-TCTCCTTCTAGCCTCCGCTAGTC-3
(26).
The intersample variation was monitored by parallel PCRs measuring total cellular DNA with primers specific for HLA (25) after
25 cycles of amplification.
 |
Results |
Incubation of human monocytes with an optimal concentration of IL-10 (10 ng/ml) for 4 h increased the expression of CCR1, 2, and 5 as evaluated by Northern blot
analysis (Fig. 1 A). CCR3 and CCR4 are expressed at very
low levels in human monocytes (15) and their expression
was not induced by IL-10 (data not shown). No major variations in the expression of CXCR2 were detectable in 3 different donors (Fig. 1 A). In one experiment a partial reduction of CXCR4 mRNA levels was detected (Fig. 1 A).
Because of the peculiarity of CCR5 in terms of ligands and
its relevance as HIV fusion cofactor, subsequent studies
were conducted on this receptor. The effect of IL-10 was
concentration dependent (effective concentration [EC]50 = 0.3 ± 0.1 ng/ml; 0.015 nM) and fast, already detectable after 30 min and reaching a plateau after 2 h of stimulation, with a maximal increase observed at 10 ng/ml (0.5 nM) IL-10
(Fig. 1, B and C). The estimated half-life of CCR5 mRNA
was 165 min and was augmented to 260 min (n = 2) after
exposure to IL-10 (Fig. 1 D). In contrast, the rate of nuclear transcription of the gene, as investigated by nuclear
runoff analysis, was not affected (Fig. 1 E).

View larger version (25K):
[in this window]
[in a new window]

View larger version (33K):
[in this window]
[in a new window]

View larger version (28K):
[in this window]
[in a new window]

View larger version (38K):
[in this window]
[in a new window]

View larger version (77K):
[in this window]
[in a new window]
|
Fig. 1.
Selective upregulation of CC chemokine receptors by IL-10. (A) Monocytes were stimulated with 10 ng/ml IL-10 for 4 h before Northern
blot analysis. (B) Monocytes were stimulated with different concentrations of IL-10 for 4 h. (C) Monocytes were stimulated with 10 ng/ml IL-10 for different times. (D) Monocytes were incubated in the presence or absence of IL-10 (10 ng/ml) for 3 h and then Actinomycin-D (1 µg/ml; ActD; Sigma)
was added for the indicated times. (E) Nuclear runoff analysis of CCR1, 2, and 5 genes. Human monocytes were incubated with 10 ng/ml IL-10 for different periods as indicated.
|
|
Having observed that IL-10 selectively upregulated expression of the CC chemokine receptors CCR1, 2, and 5, it was important to investigate the functional relevance of
this enhancement. As shown in Fig. 2, IL-10-treated monocytes responded better to CC chemokines in terms of chemotactic migration (Fig. 2 A) and intracellular calcium transients (data not shown). The effect was best observed when
suboptimal agonist concentrations were used (e.g., 1 and 10 ng/ml for MCP-1 and MIP-1
, respectively). At the concentration of 10 ng/ml, IL-10-treated monocytes showed
an increase of 237 and 189% in chemotaxis above control
values for MCP-1 and MIP-1
, respectively. It is noteworthy that IL-10 pretreatment did not appreciably affect the
spontaneous migration of monocytes. In agreement with
these results, IL-10 substantially increased the expression of
CCR5 evaluated by both cytofluorimetric analysis (Fig. 2,
B and C) and by ligand binding assays with radiolabeled MIP-1
(13,864 ± 3,257 and 22,925 ± 3,804 receptors
per cell, P <0.01; with identical affinity 2.6 ± 0.9 and 3.4 ± 0.9 nM for control and treated cells, 20 ng/ml for 20 h, respectively). The effect of IL-10 on CCR5 surface expression was also observed when monocytes were exposed to
HIV BaL (Fig. 2 C).

View larger version (37K):
[in this window]
[in a new window]
|
Fig. 2.
Augmented expression of functional CC chemokine receptors and upregulation of HIV infection by IL-10. (A) Effect on chemotaxis. Monocytes were cultured for 16 h with medium or IL-10 (10 ng/ ml) and tested for chemotaxis to a suboptimal concentration of MCP-1
(1 ng/ml) or MIP-1 (10 ng/ml). Values are mean (± SE, three replicates) number of migrated cells after subtraction of spontaneous migration
that was not affected by IL-10 (data not shown). (B) Surface expression of
CCR5. Monocytes were exposed to IL-10 (10 ng/ml) for 16 h and surface expression was determined by flow cytometry using the 5C7-18 anti-CCR5 mAb. Dots, irrelevant mAb; broken line, control monocytes
stained with anti-CCR5; continuous line, IL-10-treated monocytes
stained with anti-CCR5. (C) Kinetics of CCR5 expression in control and
HIV-infected monocytes cultured for the time indicated with 10 ng/ml
IL-10. Results from a single donor representative of two to four tested are
expressed as relative fluorescence index as described in Materials and
Methods. (D) Effect of IL-10 on HIV infection of monocytes. Cells were
incubated in 48-well tissue culture plastic plates in the presence or absence of IL-10 (0.1 ng/ml) for 6 h before incubation for 30 min with RANTES (200 ng/ml) and infection with the macrophage-tropic BaL strain of HIV-1. Mg2+-dependent reverse transcriptase activity was measured in the culture supernatants (24).
|
|
The macrophage-tropic HIV-1 strain BaL (27) was used
to investigate whether IL-10-induced upregulation of CC
chemokine receptors affected the susceptibility of monocytes
to infection. A productive HIV infection was observed in
human peripheral blood monocytes that were incubated
with the virus shortly after isolation. IL-10 caused a clear
enhancement of virus multiplication, as previously reported
using monocyte-derived macrophages (24). A panel of CC
chemokines, including MIP-1
, MIP-1
, and MCP-1 was
tested in parallel to RANTES for their capacity to interfere
with HIV replication in control and in IL-10-stimulated
monocytes. RANTES caused a detectable, although modest, delay in the onset of virus production in untreated
monocytes and completely inhibited IL-10-induced upregulation of viral replication (Fig. 2 D). In comparison, the other tested chemokines showed a very modest effect on
viral replication (not shown). In this regard, the higher potency of RANTES as HIV inhibitor compared to other
chemokines has been recently reported (28). In addition,
AOP-RANTES, a RANTES mutein with antagonistic activity (21), completely abolished HIV replication in control as well as IL-10-treated monocytes (data not shown).
To validate this hypothesis, we analyzed the kinetics
of proviral HIV DNA accumulation in control versus
IL-10-stimulated monocytes. Proviral HIV DNA was readily
demonstrated 16 h after infection (a time frame compatible
with a single round of HIV replication) in IL-10-stimulated, but not control, monocytes, whereas similar signals
were observed in control and IL-10-treated cells 40 h after
infection (Fig. 3). AOP-RANTES substantially suppressed
HIV DNA accumulation in both control and IL-10-stimulated cells (Fig. 3), as a result of interference with viral entry. CCR5 membrane expression, which was already upregulated after 6 h of incubation with IL-10, remained
elevated during the subsequent 40 h. HIV infection resulted
only in a minor decrease of IL-10-induced CCR5 expression (Fig. 2 C).

View larger version (44K):
[in this window]
[in a new window]
|
Fig. 3.
Kinetics of proviral HIV DNA accumulation. Monocytes
were stimulated with IL-10 (10 ng/ml) for 6 h in the presence and absence of 200 ng/ml of AOP-RANTES for 30 min before infection with
HIV-1 Bal. Aliquots were harvested 1, 16, and 40 h after infection and tested for proviral DNA synthesis.
|
|
 |
Discussion |
The results presented here show that the potent antiinflammatory and immunosuppressive cytokine IL-10 can
upregulate expression of functional CCR1, 2, and 5 receptors in human monocytes. The effect of IL-10 was selective
in that CCR3 and 4, which are normally expressed at very
low levels, were not induced, and, in one experiment, CXCR4, which is present and functional in monocytes,
was slightly decreased. The modulatory action of IL-10 was
mediated by prolongation of mRNA half-life. This observation, together with recent findings with prototypic pro-
and antiinflammatory molecules (15 and our unpublished
observations, see also below), indicates that receptor mRNA
stability is a crucial set point for the action of chemokines.
IL-10 has been shown to have divergent effects on HIV
replication in macrophages in vitro, depending on experimental conditions such as cytokine concentrations (24, 29-
31). In this study, we found that IL-10 promoted a productive infection of monocytes by the macrophage-tropic HIV
BaL strain, an effect that was associated with an increase of
viral entry. Since the IL-10-mediated enhancement was
inhibited by RANTES and completely abolished by AOP-RANTES, we infer that upregulation of CCR5 plays a
major role in IL-10 enhancement of HIV replication, at
least under these experimental conditions. A.S. Fauci has
recently observed a transient decrease of circulating HIV
virions (viremia) in HIV-infected individuals who were
injected intravenously with IL-10 (Fauci, A.S., personal communication). Our results suggest a potential mechanism perhaps contributing to this in vivo effect, i.e., the
enhancement of cell surface expression of CCR5 and other
chemokine receptors by IL-10 may favor the sequestration
and, eventually, the entry of free circulating virions. However, it should be stressed that IL-10 may exert multiple effects on HIV infection, such as the inhibition of HIV replication dependent upon release of proinflammatory cytokines,
as previously reported (29), in addition to the effect observed in this study.
The in vivo relevance of IL-10-mediated upregulation
of CC chemokine receptors/HIV fusion coreceptors is a matter of speculation. Subjects homozygous for the
32 mutation do not express functional CCR5 and are resistant to
infection after multiple exposure to HIV (32), whereas
heterozygous for this mutation tend to have a decrease rate
of disease progression (35, 36). IL-10 production in mucosal tissues plays a key role in the control of inflammation, as indicated by the inflammatory bowel disease observed in
IL-10
/
mice (18). We suggest that this tonic production
of IL-10 may maintain CCR5 expression in mucosal tissues, contributing to the dominant role of this fusion coreceptor in primary HIV infection.
In addition to IL-10, we recently found that other molecules with antiinflammatory activity, such as glucocorticoid
hormones, upregulate certain CC chemokine receptors
(e.g., CCR2; data not shown). These agents concomitantly
inhibit chemokine (e.g., MCP-1) production in monocytes
(7, 8). Reciprocally, at least certain prototypic primary proinflammatory agents (endotoxin, TNF) induce chemokine
production and inhibit receptor expression (references 12,
15 and our unpublished observations). Hence, an emerging paradigm indicates that at least some pro- and antiinflammatory molecules exert reciprocal and opposing influences
on chemokine ligand production and receptor expression.
This interplay may serve as a negative feedback mechanism
and as a means to regulate the efflux of mononuclear phagocytes from sites of inflammation. The regulation of chemokine receptor expression mediated at the level of transcript
stability may represent a novel target for pharmacological
intervention in inflammatory diseases and viral infections.
Address correspondence to Dr. Alberto Mantovani, Istituto di Ricerche Farmacologiche `Mario Negri', via
Eritrea 62, 20157 Milan, Italy. Phone: 39-2-3901-4493; Fax: 39-2-354-6277; E-mail: mantovani{at}irfmn.mnegri.it
Received for publication 1 August 1997 and in revised form 17 November 1997.
S. Sozzani and S. Ghezzi contributed equally to this work.
This work was supported by Associazione Italiana per la Ricerca sul Cancro (AIRC) and by special project
AIDS from Istituto Superiore Sanità, grant Nos. 9306-06 (to G. Poli) and 9304-83 (to A. Mantovani).
| 1.
|
Baggiolini, M.,
B. Dewald, and
B. Moser.
1997.
Human chemokines: an update.
Annu. Rev. Immunol.
15:
675-705
[Medline].
|
| 2.
|
Ben-Baruch, A.,
D.F. Michiel, and
J.J. Oppenheim.
1995.
Signals and receptors involved in recruitment of inflammatory cells.
J. Biol. Chem.
270:
11703-11706
[Free Full Text].
|
| 3.
|
Rollins, B.J..
1997.
Chemokines.
Blood.
90:
909-928
[Free Full Text].
|
| 4.
|
Premack, B.A., and
T.J. Schall.
1996.
Chemokine receptors:
gateways to inflammation and infection.
Nat. Med.
2:
1174-1178
[Medline].
|
| 5.
|
Feng, Y.,
C.C. Broder,
P.E. Kennedy, and
E.A. Berger.
1996.
HIV-1 entry cofactor: functional cDNA cloning of a
seven-transmembrane, G protein-coupled receptor.
Science.
272:
872-877
[Abstract].
|
| 6.
|
DSouza, M.P., and
V.A. Harden.
1996.
Chemokines and
HIV-1 second receptors: confluence of two fields generates optimism in AIDS research.
Nat. Med.
2:
1293-1300
[Medline].
|
| 7.
|
Baggiolini, M.,
B. Dewald, and
B. Moser.
1994.
Interleukin-8 and related chemotactic cytokines CXC and CC chemokines.
Adv. Immunol.
55:
99-179
.
|
| 8.
|
Sozzani, S.,
P. Allavena,
P. Proost,
J. Van Damme, and
A. Mantovani.
1996.
Chemokines as targets for pharmacological
intervention.
Prog. Drug Res.
45:
53-80
.
|
| 9.
|
Murphy, P.M..
1994.
The molecular biology of leukocyte chemoattractant receptors.
Annu. Rev. Immunol.
12:
593-633
[Medline].
|
| 10.
|
Gerard, C., and
N.P. Gerard.
1994.
C5A anaphylatoxin and
its seven transmembrane-segment receptor.
Annu. Rev. Immunol.
12:
775-808
[Medline].
|
| 11.
|
Mackay, C.R..
1996.
Chemokine receptors and T cell chemotaxis.
J. Exp. Med.
184:
799-802
[Free Full Text].
|
| 12.
|
Lloyd, A.R.,
A. Biragyn,
J.A. Johnston,
D.D. Taub,
L.L. Xu,
D. Michiel,
H. Sprenger,
J.J. Oppenheim, and
D.J. Kelvin.
1995.
Granulocyte-colony stimulating factor and lipopolysaccharide regulate the expression of interleukin 8 receptors on
polymorphonuclear leukocytes.
J. Biol. Chem.
270:
28188-28192
[Abstract/Free Full Text].
|
| 13.
|
Loetscher, P.,
M. Seitz,
M. Baggiolini, and
B. Moser.
1996.
Interleukin-2 regulates CC chemokine receptor expression
and chemotactic responsiveness in T lymphocytes.
J. Exp. Med.
184:
569-577
[Abstract/Free Full Text].
|
| 14.
|
Polentarutti, N.,
P. Allavena,
G. Bianchi,
G. Giardina,
A. Basile,
S. Sozzani,
A. Mantovani, and
M. Introna.
1997.
IL-2- regulated expression of the monocyte chemotactic protein-1
receptor (CCR2) in human NK cells: characterization of a
predominant 3.4-Kb transcript containing CCR2B and
CCR2A sequences.
J. Immunol.
158:
2689-2694
[Abstract].
|
| 15.
|
Sica, A.,
A. Saccani,
A. Borsatti,
C.A. Power,
T.N.C. Wells,
W. Luini,
N. Polentarutti,
S. Sozzani, and
A. Mantovani.
1997.
Bacterial lipopolysaccharide rapidly inhibits expression
of C-C chemokine receptors in human monocytes.
J. Exp.
Med.
185:
969-974
[Abstract/Free Full Text].
|
| 16.
|
Mosmann, T.R..
1994.
Properties and functions of interleukin-10.
Adv. Immunol.
56:
1-26
[Medline].
|
| 17.
|
de Vries, J.E..
1995.
Immunosuppressive and anti-inflammatory properties of interleukin-10.
Ann. Med.
27:
537-541
[Medline].
|
| 18.
|
Geissler, K..
1996.
Current status of clinical development of
interleukin-10.
Curr. Opin. Hematol.
3:
203-208
.
[Medline] |
| 19.
|
Sozzani, S.,
D. Zhou,
M. Locati,
M. Rieppi,
P. Proost,
M. Magazin,
N. Vita,
J. Van Damme, and
A. Mantovani.
1994.
Receptors and transduction pathways for monocyte chemotactic protein-2 and monocyte chemotactic protein-3: similarities and differences with MCP-1.
J. Immunol.
152:
3615-3622
[Abstract].
|
| 20.
|
Heath, H.,
S.X. Qin,
P. Rao,
L.J. Wu,
G. Larosa,
N. Kassam,
P.D. Ponath, and
C.R. Mackay.
1997.
Chemokine receptor
usage by human eosinophils: the importance of CCR3 demonstrated using an antagonistic monoclonal antibody.
J. Clin.
Invest.
99:
178-184
[Medline].
|
| 21.
|
Simmons, G.,
P.R. Clapham,
L. Picard,
R.E. Offord,
M.M. Rosenkilde,
T.W. Schwartz,
R. Buser,
T.N.C. Wells, and
A.E. Proudfoot.
1997.
Potent HIV inhibition of HIV infectivity in macrophages and lymphocytes by a novel CCR5 antagonist.
Science.
276:
276-279
[Abstract/Free Full Text].
|
| 22.
|
Choe, H.,
M. Farzan,
Y. Sun,
N. Sullivan,
B. Rollins,
P.D. Ponath,
L.J. Wu,
C.R. Mackay,
G. Larosa,
W. Newman, et al
.
1996.
The -chemokine receptors CCR3 and CCR5 facilitate infection by primary HIV-1 isolates.
Cell.
85:
1135-1148
[Medline].
|
| 23.
|
Deng, H.K.,
R. Liu,
W. Ellmeier,
S. Choe,
D. Unutmaz,
M. Burkhart,
P. Di Marzio,
S. Marmon,
R.E. Sutton,
C.M. Hill, et al
.
1996.
Identification of a major co-receptor for primary
isolates of HIV-1.
Nature.
381:
661-666
[Medline].
|
| 24.
|
Weissman, D.,
G. Poli, and
A.S. Fauci.
1995.
IL-10 synergizes with multiple cytokines in enhancing HIV production in cells of monocytic lineage.
J. Acquired Immune Defic. Syndr.
Hum. Retrovirol.
9:
442-449
[Medline].
|
| 25.
| Graziosi, C., G. Pantaleo, and A. S. Fauci. 1993. Detection of
HIV DNA and RNA using PCR. In Current Protocols of Immunology. J.E. Coligan, A.M. Kruisbeek, D.H. Margulies, E.M. Shevach, and W. Strober, editors. Greene Publishing Assoclates and Wiley-Interscience, New York. 12.6.1-12.6.12.
|
| 26.
|
Saksela, K.,
E. Muchmore,
E. Girard,
P. Fultz, and
D. Baltimore.
1993.
High viral load in lymph nodes and latent human immunodeficiency virus (HIV) in peripheral blood cells
of HIV-1-infected chimpanzees.
J. Virol.
67:
7423-7427
[Abstract/Free Full Text].
|
| 27.
|
Gartner, S.,
P. Markovits,
D.M. Markovitz,
M.H. Kaplan,
R.C. Gallo, and
M. Popovic.
1986.
The role of mononuclear
phagocytes in HTLV-III/LAV infection.
Science.
233:
215-219
[Abstract/Free Full Text].
|
| 28.
|
Scarlatti, G.,
E. Tresoldi,
A. Biorndal,
R. Fredriksson,
C. Colognesi,
H. Kui,
Deng,
M.S. Malnati,
A. Plebani,
A.G. Siccardi,
D.R. Littman, et al
.
1997.
In vivo evolution of
HIV-1 co-receptor usage and sensitivity to chemokine-mediated suppression.
Nat. Med.
3:
1259-1265
[Medline].
|
| 29.
|
Weissman, D.,
G. Poli, and
A.S. Fauci.
1994.
Interleukin 10 blocks HIV replication in macrophages by inhibiting the autocrine loop of tumor necrosis factor and interleukin 6 induction of virus.
AIDS Res. Hum. Retroviruses.
10:
1199-1206
[Medline].
|
| 30.
|
Kootstra, N.A.,
A.B. van't Wout,
H.G. Huisman,
F. Miedema, and
H. Schuitemaker.
1994.
Interference of interleukin-10
with human immunodeficiency virus type 1 replication in
primary monocyte-derived macrophages.
J. Virol.
68:
6967-6975
[Abstract/Free Full Text].
|
| 31.
|
Saville, M.W.,
K. Taga,
A. Foli,
S. Broder,
G. Tosato, and
R. Yarchoan.
1994.
Interleukin-10 suppresses human immunodeficiency virus-1 replication in vitro in cells of the monocyte/macrophage lineage.
Blood.
83:
3591-3599
[Abstract/Free Full Text].
|
| 32.
|
Samson, M.,
F. Libert,
B.J. Doranz,
J. Rucker,
C. Liesnard,
C.M. Farber,
S. Saragosti,
C. Lapoumeroulie,
J. Cognaux,
C. Forceille, et al
.
1996.
Resistance to HIV-1 infection in
Caucasian individuals bearing mutant alleles of the CCR-5
chemokine receptor gene.
Nature.
382:
722-725
[Medline].
|
| 33.
|
Liu, R.,
W.A. Paxton,
S. Choe,
D. Ceradini,
S.R. Martin,
R. Horuk,
M.E. Macdonald,
H. Stuhlmann,
R.A. Koup, and
N.R. Landau.
1996.
Homozygous defect in HIV-1 coreceptor accounts for resistance of some multiply-exposed individuals to HIV-1 infection.
Cell.
86:
367-377
[Medline].
|
| 34.
|
Dean, M.,
M. Carrington,
C. Winkler,
G.A. Huttley,
M.W. Smith,
R. Allikmets,
J.J. Goedert,
S.P. Buchbinder,
E. Vittinghoff,
E. Gomperts, et al
.
1996.
Genetic restriction on
HIV-1 infection and progression to AIDS by a deletion allele
of the CKR5 structural gene.
Science.
273:
1856-1862
[Abstract/Free Full Text].
|
| 35.
|
Michael, N.L.,
G. Chang,
L.G. Louie,
J.R. Mascola,
D. Dondero,
D.L. Birx, and
H.W. Sheppard.
1997.
The role of
viral phenotype and CCR-5 gene defects in HIV-1 transmission and disease progression.
Nat. Med.
3:
338-342
[Medline].
|
| 36.
| Morawetz, R.A., P.G. Rizzardi, D. Glauster, O. Rutschmann,
B. Hirschel, L. Perrin, M. Opravil, M. Flepp, J. von Overbeck, M.P. Glauster, et al. 1998. Genetic polymorphism of CCR5
gene and HIV disease: the heterozygous (CCR5/ ccr5) genotype is neither essential nor sufficient for protection against
disease progression. Eur. J. Immunol. In press.
|